GS-5816

5 Drugs That Investors May Be Undervaluing
Motley Fool
Mon, 07/13/15 - 11:04 am
Amicus Therapeutics
Galafold
Receptos
ozanimod
GS-5816
Gilead Sciences
ACH-3102
Achillion
Ophthotech
Fovista
Merck and Gilead square off in battle of the next-next-gen hep C combos
Fierce Biotech
Thu, 04/23/15 - 09:50 am
Merck
Gilead Sciences
hepatitis C
grazoprevir/elbasvir
GS-5816
GS-9857